12/13/2025
đź’Ż
First phase 3 data for retatrutide are here folks. This drug is a barn burner. This was only 68 weeks and was geared towards osteoarthritis of the knee. Massive pain improvements and getting close bariatric surgery levels of weight loss AND huge cardiometabolic improvements.
I have had many clinical trial patients on this drug and of course you’ve heard about the people taking the grey market research peptide versions (personally wouldn’t recommend). Anyway, we will cover this on the podcast in more depth but this is the drug I’m most excited for. Let it 🔥
As a reminder, this is a triple receptor agonist. GLP-1. GIP. And glucagon. Tirzepatide is GLP-1 and GIP. The glucagon component may be increasing actual metabolic rate so beyond just appetite reduction. Very cool.